First in-vivo gene therapy administered in ‘historic event’
Allergan and Editas commence a first-in-man trial for CRISPR gene therapy for patients with inherited eye condition.
Allergan and Editas commence a first-in-man trial for CRISPR gene therapy for patients with inherited eye condition.